Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

Someone holding a Chilean flag, for article on leprosy elimination

Chile becomes the first country in the Americas to eliminate leprosy, WHO verifies

By / / Good News For Humankind

After more than three decades without a locally acquired case, Chile has become just the second country in the world — after Jordan — to be officially verified by the World Health Organization as having eliminated leprosy.
The verification, announced jointly by WHO and the Pan American Health Organization, marks the end of a long arc. Chile’s last locally acquired case was reported in 1993, originating on Rapa Nui (Easter Island), where the disease first arrived in the late 19th century. The win came from decades of patient work: ongoing surveillance, free multidrug treatment provided through PAHO since 1995, trained clinicians, and care that prioritized dignity alongside diagnosis.
Globally, leprosy still affects more than 200,000 people a year, mostly in tropical regions, and WHO has urged Chile to keep its surveillance sharp in case the disease ever returns. But for now, an ancient illness has been pushed to the margins of one country’s medical history — and a model has been built for others to follow.

New York City park, for article on urban forest plan

New York City’s first urban forest plan targets its hottest, least-shaded blocks

By / / Good News For Humankind

New York City’s first Urban Forest Plan aims to grow tree canopy from 23.4% to 30% of the city’s surface by 2040, with a focus on neighborhoods that have been left in the sun for too long. Right now, environmental justice communities sit under about 19% canopy cover, while wealthier areas enjoy 26% — a gap you can feel on a hot summer afternoon. The plan protects existing trees, expands planting on streets and private land, and trains residents, including NYCHA tenants, to care for the urban forest. It’s a hopeful reminder that shade, cooler air, and cleaner streets are infrastructure every neighborhood deserves.

Depiction of DNA, for article on gene therapy for inherited deafness

U.S. FDA approves first-ever gene therapy for inherited deafness, free to patients

By / / Good News For Humankind

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families.
In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within six months, and five regained normal hearing, including the ability to hear whispers. Instead of charging the millions per child that’s common for rare-disease therapies, Regeneron chose a different path. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag. Called Otarmeni, the one-time treatment uses two harmless viruses to deliver working copies of the OTOF gene deep into the inner ear, restoring otoferlin, the protein the cochlea needs to turn sound into signals the brain can read. Its maker, Regeneron, says it will offer the therapy free to patients in the U.S. Doctors who ran the trial described children responding to their parents’ voices, and to music, for the first time.
This particular genetic form of deafness is rare, affecting roughly 50 babies born in the U.S. each year. But researchers believe the breakthrough cracks open the door to gene therapies for many other inherited conditions worldwide.

Finger prick insulin injection, for article on once-weekly insulin

Once-weekly insulin wins U.S. approval, cutting 365 injections a year to 52

By / / Good News For Humankind

Once-weekly insulin just became reality in the U.S., dropping the routine for many adults with type 2 diabetes from 365 shots a year to about 52. The FDA approved Awiqli after four phase 3 trials, covering 2,680 adults, found it matched or outperformed daily basal insulin in lowering blood glucose. For people already taking a weekly GLP-1 medication, pairing the two could mean far fewer injection days and one less thing to remember. Doctors are urging thoughtful, individualized use, especially around hypoglycemia risk and affordability. Still, with more than 500 million adults living with diabetes worldwide, treatments that make daily life easier are a quietly powerful step forward for global health.

Cancer patient reading a book, for article on pre-surgery immunotherapy

Bowel cancer patients see zero relapses three years after new immunotherapy

By / / Good News For Humankind

Bowel cancer patients in a small U.K. trial saw zero relapses nearly three years after receiving immunotherapy before surgery — a striking result for all 32 participants, even those who still had traces of cancer after treatment. By comparison, the standard path of surgery followed by chemotherapy sees roughly one in four patients relapse within three years. The trial focused on people with a specific genetic profile that makes tumors more visible to the immune system, sparing them months of post-surgery chemo. One participant described the cancer “melting away” before his operation. If larger trials confirm the approach, it could reshape how a meaningful slice of bowel cancer cases are treated worldwide.

Tunisian flag, for article on trachoma elimination

Tunisia eliminates trachoma as a public health problem

By / / Good News For Humankind

Trachoma is officially gone as a public health problem in Tunisia — a disease that once affected at least half the country’s population. The World Health Organization has now validated Tunisia as the 31st country to eliminate it, and the first neglected tropical disease ever crossed off the country’s list. The win came from decades of patient work: nationwide screening, eye care woven into schools and clinics, hygiene outreach, and steady improvements in water and sanitation. Around the world, roughly 1.9 million people still live with trachoma-related blindness or visual impairment, and 136 million remain at risk. Tunisia’s story is proof that preventable blindness doesn’t have to stay that way — and a hopeful nudge toward the WHO’s 2030 goal of ending trachoma everywhere.

Infant feet, for article on nirsevimab RSV infant hospitalizations

Spanish study links RSV antibody to 86% drop in infant hospitalizations

By / / Good News For Humankind

Nirsevimab, a long-acting antibody given to every infant in one Spanish region, cut RSV hospitalizations by 86% compared to previous seasons, according to a new study out of Valladolid University. Babies under six months — the group hit hardest by RSV every winter — saw the biggest drop, with pediatric intensive care admissions falling sharply too. Unlike a traditional vaccine, the shot delivers ready-made antibodies directly, which matters for newborns whose immune systems are still developing. Several European countries and the U.S. have already added it to routine infant care, and early data abroad echo the Spanish results. The remaining challenge is making sure families in lower-income countries, where RSV hits hardest, aren’t left waiting.

Eye exam, for article on trachoma elimination

Australia becomes 30th country to eliminate trachoma as a public health concern

By / / Good News For Humankind

Trachoma has officially been eliminated as a public health concern in Australia, making it the 30th country to defeat the world’s leading infectious cause of blindness. The win took nineteen years of patient work in Aboriginal and Torres Strait Islander communities, where the disease quietly persisted long after vanishing from cities. What made the difference wasn’t a miracle drug — it was Aboriginal Community Controlled Health Organizations leading the response, paired with better housing, cleaner water, and treatment designed around local realities rather than imposed from outside. Health Minister Mark Butler said the lessons will shape how Australia tackles other preventable illnesses in remote regions. For the 125 million people still living in trachoma-endemic areas worldwide, Australia’s playbook offers something rare: proof that community-led care actually works.

Two sets of hand holding newborn baby, for article on Coartem Baby malaria treatment

W.H.O. approves world’s first malaria treatment for newborn babies

By / / Good News For Humankind

Newborn babies with malaria finally have a medicine made just for them. Coartem Baby, a cherry-flavored tablet that dissolves into breast milk or water, just earned World Health Organization prequalification — a green light that opens the door to public health systems across sub-Saharan Africa. For decades, doctors had to guess at doses using drugs built for older children, even as research showed infants were getting infected too. Ghana has already begun rolling it out, and Novartis has committed to what it calls “largely not-for-profit pricing” in malaria-endemic regions. Alongside new vaccines and better bed nets, it’s a quiet but meaningful sign that the fight against malaria — which still kills hundreds of thousands of children a year — is reaching the patients it had long overlooked.

Holding a nasal spray, for article on prehospital stroke nasal spray

Hong Kong researchers develop world-first nasal spray for stroke, cutting damage 80%

By / / Good News For Humankind

A nasal spray for stroke, developed at the University of Hong Kong, cut brain damage by more than 80% when given within 30 minutes of an ischemic stroke in preclinical studies. The idea is beautifully simple: tiny particles travel from the nose directly along nerve pathways to the brain, sidestepping the blood-brain barrier that derails most neurological drugs. Designed to be as easy to use as an EpiPen, it could let a bystander start protecting brain cells before the ambulance even arrives. Clinical trials are still years away, but if it holds up, this kind of “protection-first” thinking could reshape emergency care for stroke patients everywhere — especially the 85% who currently never reach treatment in time.